<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H07E0EB64E56C4CB0A5722F0F99BEF4C7" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 HR 9634 IH: Federal Clarity for Kratom Consumers Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2022-12-20</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">117th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 9634</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20221220">December 20, 2022</action-date><action-desc><sponsor name-id="P000607">Mr. Pocan</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To protect access to kratom.</official-title></form><legis-body id="H84F54AC44C894C6FB6061DDEC5BFD845" style="OLC"><section id="H1DD15DAE9F284FF7ADC9611D03B78841" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Federal Clarity for Kratom Consumers Act</short-title></quote>.</text></section><section id="HE339FF93DAE842E6A9F79BA7D114EF86"><enum>2.</enum><header>Access to kratom</header><subsection commented="no" display-inline="no-display-inline" id="HE5BC6EC816404F168E004E512D5E7A7F"><enum>(a)</enum><header>Openness in research</header><paragraph commented="no" display-inline="no-display-inline" id="H63BB132ABD894094B8573F4BEC5C38D2"><enum>(1)</enum><header display-inline="yes-display-inline">In general</header><text>During the period that begins 30 days after the date of enactment of this Act and ends 90 days after such date of enactment, the Secretary, acting through the Commissioner, shall hold at least one hearing that provides an open forum for the discussion on the current scientific data and information about safety and use of products containing kratom or kratom-derived products marketed as a food, dietary ingredient, or dietary supplement.</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HA3C63DA1B0B74052A8954357FB0E5DC2"><enum>(2)</enum><header>Hearing requirements</header><text display-inline="yes-display-inline">The hearing under paragraph (1) shall—</text><subparagraph commented="no" display-inline="no-display-inline" id="H6F8D58E887254A1CB6A7A91925080376"><enum>(A)</enum><text display-inline="yes-display-inline">include input from leading scientific researchers on kratom and kratom-derived products; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HA1BC0C2C907846BB8CB84112F12C8778"><enum>(B)</enum><text display-inline="yes-display-inline">consider—</text><clause commented="no" display-inline="no-display-inline" id="H673B4CC9035D45E7A7EE7769C88706C9"><enum>(i)</enum><text display-inline="yes-display-inline">how many individuals in the United States consume kratom and kratom-derived products;</text></clause><clause commented="no" display-inline="no-display-inline" id="H0C76E02A60E84BE4BB94C126FFAFF247"><enum>(ii)</enum><text display-inline="yes-display-inline">the scope, scale, and degree of dependence or addiction associated with kratom, mitragynine, and 7–hydroxymitragynine;</text></clause><clause commented="no" display-inline="no-display-inline" id="H64C83D0E86A642C09307773424E7FD8B"><enum>(iii)</enum><text display-inline="yes-display-inline">the causality of deaths in which kratom or kratom-derived products are associated, including instances in which—</text><subclause id="HA796C0A5A7E4436F9BC58E0B22E63744"><enum>(I)</enum><text>a kratom-containing product or kratom-derived product was consumed together with legal or illegal drugs; or</text></subclause><subclause commented="no" display-inline="no-display-inline" id="HB9781E4AD4D74754B3F17472BB1043BA"><enum>(II)</enum><text display-inline="yes-display-inline">the kratom-containing product or kratom-derived product consumed was contaminated with a different non-drug adulterant known to endanger health;</text></subclause></clause><clause commented="no" display-inline="no-display-inline" id="HBA588147825648CE9101F0F6895F8B8D"><enum>(iv)</enum><text display-inline="yes-display-inline">whether use of kratom or kratom-derived products is directly linked to the use of more dangerous scheduled substances;</text></clause><clause commented="no" display-inline="no-display-inline" id="HF206AE7AA9DB479491E8B372AF0656AD"><enum>(v)</enum><text display-inline="yes-display-inline">any adverse health impacts that could be expected if kratom or kratom-derived were no longer available; and</text></clause><clause commented="no" display-inline="no-display-inline" id="H52D5E6F434E8465D8DAF545FC86D642D"><enum>(vi)</enum><text display-inline="yes-display-inline">the potential health and wellness benefits of kratom and kratom-derived products.</text></clause></subparagraph></paragraph><paragraph id="H034E6871967648F4B8DF9C6B71FCB98C"><enum>(3)</enum><header>Public docket</header><text>Not later than 30 days after the date of enactment of this Act, the Secretary shall open a public docket for submission of public comments for consideration at the hearing under paragraph (1). The Secretary shall leave such public docket open for comments for not fewer than 30 days before the hearing takes place.</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H7EC258BB05A44884BA68B3BC657D8FB6"><enum>(4)</enum><header>Publication of information</header><text>The Secretary shall publish on the website of the Food and Drug Administration the transcripts of all hearings conducted pursuant to paragraph (1), subject to section 552(b) of title 5, United States Code.</text></paragraph></subsection><subsection id="H2E3B1B4003EB401B8E5FEC84721E5AA2"><enum>(b)</enum><header>Task force</header><paragraph commented="no" display-inline="no-display-inline" id="H119F6357A615432286D25515165A5E3D"><enum>(1)</enum><header>Establishment</header><text display-inline="yes-display-inline">Not later than 30 days after the date of enactment of this Act, the Secretary shall convene a task force, to be known as the <quote>Kratom Research Task Force</quote>, to coordinate kratom-related research conducted or supported by the Federal Government.</text></paragraph><paragraph id="H29484F32F0664908864D55FA612B8CA6"><enum>(2)</enum><header>Reports on kratom research</header><subparagraph commented="no" display-inline="no-display-inline" id="H324F480B78D84E1CBA963FC7D8C80CA0"><enum>(A)</enum><header>Initial report</header><text display-inline="yes-display-inline">Not later than 90 days after the date of enactment of this Act, the Kratom Research Task Force shall submit to Congress, the Secretary, and the Commissioner a report that details all federally funded kratom-related research that has begun or been completed prior to such date of enactment. </text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H2833DCEBF3A547B8BF321B7E99B2F375"><enum>(B)</enum><header>Subsequent quarterly reports</header><text>Not later than 90 days after submission of the report under subparagraph (A), and quarterly thereafter, the Kratom Research Task Force shall submit to Congress, the Secretary, and the Commissioner a report that includes—</text><clause commented="no" display-inline="no-display-inline" id="H63D702AD2B8A4DF986DE29F365B719BB"><enum>(i)</enum><text display-inline="yes-display-inline">a progress report on all federally funded kratom-related research and findings made during the applicable quarter; and</text></clause><clause commented="no" display-inline="no-display-inline" id="HB8B7C92D13754C53B0C66F036EBC90F5"><enum>(ii)</enum><text display-inline="yes-display-inline">an analysis of the results of all such research.</text></clause></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H877078F3502146DDBDCFD847D98D2DEE"><enum>(3)</enum><header>Public meetings</header><text>The Kratom Research Task Force shall convene public meetings with appropriate experts and stakeholders to increase public awareness concerning the current state of kratom-related research.</text></paragraph><paragraph id="HC978E5274AC44669A244AD3B8F83EFA1"><enum>(4)</enum><header>Publicly available information</header><text>The Secretary shall—</text><subparagraph commented="no" display-inline="no-display-inline" id="H3FFDD5E5D094448DA6737E41A5E98DDA"><enum>(A)</enum><text display-inline="yes-display-inline">publish the report submitted under paragraph (2)(A) on the website of the Food and Drug Administration; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H5628921B8FDE4EE7B65E4ECC2C562641"><enum>(B)</enum><text display-inline="yes-display-inline">update such website in accordance with the quarterly reports submitted under paragraph (2)(B), upon receipt of each such report.</text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HBE297F2A134D40B39EBBCE59B85DB416"><enum>(5)</enum><header>Termination of task force</header><text>On the date that is 2 years after the initial report is submitted by the Kratom Research Task Force under paragraph (2)(A), such task force shall be terminated.</text></paragraph></subsection><subsection id="H87729ADEDCD04B91A2CF83FE78356277"><enum>(c)</enum><header>Protection of kratom from current regulations</header><text>The Secretary shall not—</text><paragraph commented="no" display-inline="no-display-inline" id="H99D1DA43727645CF87737E4B34B61D8F"><enum>(1)</enum><text display-inline="yes-display-inline">impose requirements on kratom or kratom-derived products that are more restrictive than the requirements for food, dietary supplements, and dietary ingredients that apply under The Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/301">21 U.S.C. 301 et seq.</external-xref>);</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H287DFC5D7B6D452E88BD6825D9DF96F2"><enum>(2)</enum><text display-inline="yes-display-inline">treat kratom, or any product derived from or containing kratom, as an adulterated dietary supplement—</text><subparagraph commented="no" display-inline="no-display-inline" id="HC574EAF733F34312A19DD7250C8B93DA"><enum>(A)</enum><text display-inline="yes-display-inline">for containing a new dietary ingredient as described in subparagraph (B) of section 402(f)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/342">21 U.S.C. 342(f)(1)</external-xref>); or</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H0CE5BAAAF2544AEA8559CA4183238645"><enum>(B)</enum><text display-inline="yes-display-inline">pursuant to subparagraph (C) of such section 402(f)(1); or</text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H81BF0380CBF140129576288BF6FAED06"><enum>(3)</enum><text display-inline="yes-display-inline">require kratom to undergo requirements for notification as a new dietary ingredient under section 413 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/350b">21 U.S.C. 350b</external-xref>).</text></paragraph></subsection><subsection id="HFBED5A9A0EB64156B248802E7B287B37"><enum>(d)</enum><header>Protection from future administrative action</header><paragraph commented="no" display-inline="no-display-inline" id="H97025071395647C890557D8DE28FCBDE"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Any rulemaking the Secretary initiates to regulate kratom shall—</text><subparagraph id="H2AEAEB9CA1984FCBB379464721130B89"><enum>(A)</enum><text>comply with formal rulemaking requirements under section 552(a) of title 5, United States Code; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H6D9672947D204F49B51C71ADF9F5B945"><enum>(B)</enum><text display-inline="yes-display-inline">require public, in-person hearings.</text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HE57E62905AFD43A0BEC636A2F5A66E7B"><enum>(2)</enum><header>Publication of information</header><text>The Secretary shall publish on the website of the Food and Drug Administration the transcripts of all hearings conducted pursuant to paragraph (1)(B), subject to section 552(b) of title 5, United States Code.</text></paragraph></subsection><subsection id="HA3301F6B7BEA4E5C93D2C8E0BE333839"><enum>(e)</enum><header>Import alert requirements</header><text>The Secretary may not issue, implement, or enforce an import alert for a kratom or kratom-derived product unless the Secretary determines that there is a history of such kratom or kratom-derived product being adulterated as described in section 402(f)(1)(A) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/342">21 U.S.C. 342(f)(1)(A)</external-xref>), or evidence that such kratom or kratom-derived product is adulterated as described in such section. </text></subsection><subsection id="H9524B372296349C59BD30A0334EB9057" commented="no"><enum>(f)</enum><header>Nonpreemption</header><text>Nothing in this section shall preempt any State law.</text></subsection><subsection id="HD39EBC0623344A9B95E50BCDA161977D"><enum>(g)</enum><header>Definitions</header><text>In this section:</text><paragraph id="H84DC0D4804CA4D89846BB56BF2DE4813"><enum>(1)</enum><header>Secretary</header><text>The term <term>Secretary</term> means the Secretary of Health and Human Services.</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H99A4C7CE879F49FBA9320FD314931DA7"><enum>(2)</enum><header>Commissioner</header><text display-inline="yes-display-inline">The term <term>Commissioner</term> means the Commissioner of Food and Drugs.</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HBC63D6BE0A6B429F8C5F95CC4F7C3665"><enum>(3)</enum><header>Dietary supplement</header><text>The term <term>dietary supplement</term> has the meaning given such term in section 201(ff) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/321">21 U.S.C. 321(ff)</external-xref>).</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HD112DBC9BA424A20B7286245FD15E638"><enum>(4)</enum><header>Dietary ingredient</header><text display-inline="yes-display-inline">The term <term>dietary ingredient</term> means a dietary ingredient as such term is used in section 201(ff)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/321">21 U.S.C. 321(ff)(1)</external-xref>).</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H864AC5F6C10C46188937C4A303CC87AE"><enum>(5)</enum><header>Food</header><text display-inline="yes-display-inline">The term <term>food</term> has the meaning given such term in section 201(f) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/321">21 U.S.C. 321(f)</external-xref>).</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HC9B805581B6F4CAAA6C5A598995C6A04"><enum>(6)</enum><header>Kratom</header><text display-inline="yes-display-inline">The term <term>kratom</term> means the botanical Mitragyna speciosa.</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HD3EF393294BB4B9CA5DD587200F798E4"><enum>(7)</enum><header>New dietary ingredient</header><text display-inline="yes-display-inline">The term <term>new dietary ingredient</term> has the meaning given such term in section 413(d) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/350b">21 U.S.C. 350b(d)</external-xref>). </text></paragraph></subsection></section></legis-body></bill> 

